What the research found

Zinc lozenges, particularly those begun within the first day of cold symptoms, appear to reduce how long you stay sick. When zinc ions contact tissues in your mouth and throat, they may suppress viral replication and dampen inflammation locally.

Individual trials show substantial reductions: one 50-person study found colds shortened by 44% (from ~7 days to 4 days), coughs by 58%, and nasal congestion by 33%. Across seven high-dose lozenge trials, the average cold duration fell by about a third. A 2024 Cochrane systematic review placed the average reduction at roughly 2.4 days. Zinc acetate formulations performed slightly better than gluconate, though the difference was modest.

Why it matters for you

If you track illness as a biomarker of overall immune resilience—or if you're monitoring recovery time during periods of heavy training or caloric deficit—early zinc intervention is a low-cost, low-risk lever. The window is narrow: effectiveness drops sharply if you wait beyond 24 hours of onset, so this works best if you stay alert to early symptoms (scratchy throat, fatigue).

For MyKine users optimising sleep and recovery, a 3–4 day reduction in acute illness could meaningfully preserve training consistency and preserve hard-won metabolic adaptations. The cost and side-effect profile are negligible compared to most supplements in your stack.

Caveats

• Small sample size in the headline trial (n=50)
• Requires starting treatment very early (within 24 hours) to see benefit
• Benefit size declines with lower doses; "high-dose" formulations in trials were higher than many commercial products
• Effect is symptom duration reduction, not prevention—doesn't stop you catching a cold in the first place